$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
028-123456789
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
medicaldrugs
medicaldrugs
Detailed explanation of precautions when using tenofovir alafenamide tablets (Vemlidy)
2026-02-01 22:25:32
Check Details
Safety assessment and recommendations for long-term use of Lemborexant
2026-02-01 22:25:32
Check Details
Which company produces Lusutrombopag and analysis of drug sales channels
2026-02-01 22:25:32
Check Details
Omarigliptin usage, dosage and medication precautions explained
2026-02-01 22:25:32
Check Details
Detailed analysis of whether lecanemab-LEQEMBI is included in medical insurance and patient self-payment
2026-02-01 22:25:32
Check Details
Analysis of golodirsen side effects, adverse reactions and medication safety recommendations
2026-02-01 22:25:32
Check Details
An analysis of the clinical medication regimens and precautions for different patients with Vidicitomab (Aidexi)
2026-02-01 22:25:32
Check Details
Isatuximab is produced and developed by which company?
2026-02-01 22:25:32
Check Details
Whether capivasertib tablets (capivasertib) has been included in the medical insurance and reimbursement policy
2026-02-01 22:25:32
Check Details
The latest market price and reference cost of Guselkumab in 2026
2026-02-01 22:25:32
Check Details
Tenapanor reimbursement ratio and patient cost analysis
2026-02-01 22:25:32
Check Details
What is revumenib-REVUFORJ and analysis of its pharmacological effects
2026-02-01 22:25:32
Check Details
1
2
...
21
22
23
24
25
26
27
...
104
105
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
How much does a box of lenvatinib/lenvatinib capsules cost, and can it be reimbursed?
2
Which manufacturer produces Belumosudil tablets and what is the quality?
3
Tips on possible risks of using Brivaracetam
4
The application effect of Alpelisib in advanced breast cancer
5
What are the adverse reactions of fostatinib/fotantinib?
6
Is serputinib/serpatinib (Ruitu) a targeted anti-cancer drug?
7
Bezutivan combined with pembrolizumab and lenvatinib shows potential in advanced clear cell renal cell carcinoma
8
How to follow and implement the usage and dosage of Besudil/Elac
9
2026 Brivaracetam market price and price trend reference
10
How does the efficacy of Alpelisib compare with everolimus?
11
How to buy genuine fotantinib/fotantinib medicines
12
Analysis of possible resistance to serputinib/serpatinib (Ruitu)